BORDERLINE PANCREATIC FUNCTION IN CYSTIC FIBROSIS

本项目的长期目标是开发一种非侵入性方法，用于准确测量囊性纤维化（CF）患者和其他影响胰腺外分泌功能的疾病的胰腺外分泌功能不全。我们的方法基于与脂肪餐同时施用13 C标记的甘油三酯（13 C-TG）、不可吸收的标记物DyCl 3和视觉粪便标记物FD&C蓝#1（亮蓝，“BB”），然后收集和分析粪便的单个样品的13 C过量和Dy。这两个测量允许准确测定患者排泄的13 C-TG的量，而不需要连续几天定量收集粪便。在拟定项目的第I阶段，我们将检验以下假设：13 C-TG的胰水解敏感性受到TG中饱和脂肪酸链长的强烈影响。在II期研究期间，我们将测试一些具有修饰脂肪酸特征的13 C-TG，以确定TG结构对所得方法灵敏度的影响，以特定应用于评价临界外分泌胰腺功能不全。拟议的商业应用：这项研究将导致一个非侵入性的测试评估临界胰腺功能。它可用于评估胰腺功能充足但有胰腺衰竭风险的囊性纤维化患者。

The long-term objectives of this proposed project are to develop a noninvasive procedure for accurate measurement of borderline exocrine pancreatic insufficiency in cystic fibrosis (CF) patients and other disorders affecting exocrine pancreatic function. Our approach is based on simultaneous administration of a 13C-labeled triglyceride (13C-TG), the nonabsorbable marker DyCl3, and the visual fecal marker FD&C Blue #1 (Brilliant Blue, "BB") with a fatty meal followed by collection and analysis of a single sample of stool for 13C-Excess and Dy. These two measurements permit accurate determination of the amount of 13C-TG excreted by the patient without the need for quantitative collection of stools for several days. During Phase-I of the proposed project, we will test the hypothesis that the sensitivity of pancreatic hydrolysis of 13C-TG is strongly influenced by the chain-length of the saturated fatty acids present in the TG. During Phase-II research, we will test a number of 13C-TGs with modified fatty acid characteristics in order to define the effect of TG structure on the sensitivity of the resultant method for specific application to evaluation of borderline exocrine pancreatic insufficiency. PROPOSED COMMERCIAL APPLICATIONS: This research will lead to a noninvasive test for assessment of borderline pancreatic function. It has applications in evaluating cystic fibrosis patients who are pancreatic sufficient but at risk of pancreatic failure.